Rheumatoid Arthritis | Unmet Need | TNF-Alpha Refractory | US/EU | 2021

Rheumatoid arthritis (RA) patients who are refractory to one or more tumor necrosis factor-alpha (TNF-α) inhibitors are generally prescribed a non-TNF targeted therapy (e.g., Bristol Myers Squibb’s Orencia, Roche’s Actemra / RoActemra, Roche’s Rituxan / MabThera). The launch of AbbVie’s Rinvoq in the United States and Europe, along with Pfizer’s Xeljanz in Europe and Eli Lilly / Incyte’s Olumiant in both the United States and Europe, gives physicians more treatment options with a convenient route of administration (i.e., oral). However, recent safety data raise new concerns about JAK inhibitors, highlighting an unmet need for a lower risk of cardiovascular events or malignancy. Although the RA therapy market offers multiple efficacious and relatively safe agents, patients refractory to TNF-α inhibitors have limited options, even with the recent entry of newer agents; therefore, substantial unmet need remains in the treatment of tumor necrosis factor inhibitor (TNFi)-refractory RA.


  • What are the treatment drivers and goals for TNFi-refractory RA?
  • What drug attributes are key influences, which have limited impact, and which are hidden opportunities?
  • How do current therapies perform on key treatment drivers and goals for TNFi-refractory RA?
  • What are the prevailing areas of unmet need and opportunity in TNFi-refractory RA?
  • What trade-offs across different clinical attributes and price are acceptable to U.S. and European rheumatologists for a hypothetical new drug for TNFi-refractory RA?


Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 U.S. and 30 European rheumatologists fielded in February 2021

Key companies: Amgen, Pfizer, Roche, Biogen, Bristol Myers Squibb, Eli Lilly, AbbVie

Key drugs: Enbrel, Rituxan / MabThera, Orencia, Actemra / RoActemra, Xeljanz, Olumiant, Rinvoq


Login to access report

launch Related Market Assessment Reports